(Alliance News) - ReNeuron Group PLC on Wednesday said new data showed that its lead stem cell line therapy candidate can be re-programmed into a pluripotent state and differentiated into other cell types.
ReNeuron shares were 9.4% higher in London in late morning trading at 148.75 pence each.
The cell-based therapeutics developer said new data showed the phenotypic stability and scalability of a mesenchymal stem cell line derived from the company's stem cell line following re-programming to a pluripotent state.
ReNeuron has previously presented data demonstrating that its stem cell line - which is currently undergoing clinical evaluation for the treatment of stroke disability - can be successfully and rapidly re-programmed to an embryonic stem cell-like state enabling differentiation into any cell type.
"The data we are presenting at the European Society of Gene & Cell Therapy Annual Congress represent a significant advance in the use of cell re-programming to generate new allogeneic cell lines as potential therapeutic candidates," said Randolph Corteling, head of Research at ReNeuron.
He added: "Importantly, the maintenance of the immortalisation technology within these new cell lines may allow for the scaled production of 'off the shelf' allogeneic stem cells, such as haematopoietic stem cells as a potential alternative approach to those cancer immunotherapies currently in development that rely on the use of the patient's own T-cells."
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2019 Alliance News Limited. All Rights Reserved.
Reneuron (RENE)